Role of certain oral drugs in heavy menstrual bleeding.

A comparative clinical study of NÄ?gakesara CÅ«rnÌ£a and KutakÄ« CÅ«rnÌ£a in the management of AsrÌ£gdara with special reference to Dysfunctional Uterine Bleeding.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/02/031090

Enrollment

100

Registered

2021-02-08

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N938- Other specified abnormal uterine and vaginal bleeding

Interventions

Intervention1: NÄ?gakesara CÅ«rnÌ£a: Oral intake of 6 gram of NÄ?gakesara CÅ«rnÌ£a with Sahapana of NavanÄ«ta and Å?arkarÄ? and Anupana of TanÌ£dÌ£ulodaka (200 ml) before meal twice a day for 60 days

Eligibility

Inclusion criteria

Inclusion criteria: 1) Patients ready to participate in the clinical trial. 2) Patients diagnosed as dysfunctional uterine bleeding. 3) Excessive menstrual bleeding (amount >80 ml) or Prolonged menstrual bleeding ( >7 days) with or without heavy flow or Frequent menstrual cycle (interval 4) Patients presenting with inter-menstrual bleeding with or without heavy flow for 2 consecutive cycles.

Exclusion criteria

Exclusion criteria: 1) Patients with chronic systemic illness (Congestive cardiac failure, Hypertension, cirrhosis of liver, Tuberculosis endometritis, severe anaemia, chronic renal disease, Insulin dependent diabetes mellitus etc.). 2) Patients using Intrauterine contraceptive device or oral contraceptive pills (Iatrogenic). 3) Patients with uterine and pelvic pathology (Fibroid size >2 cm, endometriosis, adenomyosis, polyp, high grade cervical erosion, endometrial thickness >20 mm etc.). 4) Congenital malformations of uterus(Septate uterus, double uterus). 5) Benign and malignant growth. 6) Thyroid dysfunction (endocrinal disorders). 7) Patients having bleeding due to abortion, ectopic pregnancy, during puerperium. 8) Patients taking Anti-coagulation therapy and having haematological disorders (Leukemia, Thrombocytopenic Purpura). 9) Postmenopausal bleeding. 10) Sexually transmitted infections/Genital tract infections.

Design outcomes

Primary

Measure	Time frame
Efficacy (reduction in complaints of DUB)Timepoint: 2 months	—

Secondary

Measure	Time frame
Any adverse event reported voluntarily, observed or enquiredTimepoint: 3 months	—

Countries

India

Contacts

Public ContactDr Sonu

National Institute of Ayurveda

profphknia@gmail.com9414056362

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026